27. P I/E C O T GATE Frame P articipants I ntervention ( e xposure) C omparison (control) O utcomes T ime Time (T) T Time (T) T
28. Participant Population: Source Population: Eligible Population: 68,561 women screened from 20 outpatients/community screening centres all eligibles invited (2763) Post-menopausal, established CHD, < 80 yrs, no MI in last 6 mths, no HRT last 3 months P
29.
30. Epidemiologic evidence clinical considerations Policy issues Patient preferences X-factor: making evidence-based decisions clinical expertise: ‘putting it all together’ the art of medicine
34. GATE + RAM(M)bo O utcome I ntervention C omparator Test M aintained? R epresentation? P opulation B linded or O bjective? M easures O utcome M easures A llocation?
43. Loss follow-up (ITT vs PP) survival rate Rx B Rx A Rx B Rx A Loss or not complete 10% Rx B Rx A 80 80 80 70 80 80 survive 20 0 10 20 20 20 mortality 80.0% 100.0% 88.9% 77.8% 80% 80% PP 80% (80/100) 80% (80/100) 80% (80/100) 70% (70/100) ITT